Table I. Overview of symptoms of SARS-CoV-2 positive children (<18 years old) among VOCs.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants <18 age years old | Total | Non-Omicron variants (total) | Non-Omicron variants | | | Omicron variants (total) | Omicron variants | | | P-value |
| WTS | Alpha | Delta | Omicron BA.1 | Omicron BA.2 | Omicron BA.4/BA.5 |
|  | (N=100) | (N=34) | (N=11) | (N=8) | (N=15) | (N=66) | (N=30) | (N=16) | (N=20) |  |
| Severity |  |  |  |  |  |  |  |  |  |  |
| 0 | 18 (18.0%) | 9 (26.5%) | 5 (45.5%) | 2 (25.0%) | 2 (13.3%) | 9 (13.6%) | 7 (23.3%) | 1 (6.3%) | 1 (5.0%) | N/A |
| 1 | 75 (75.0%) | 22 (64.7%) | 6 (54.5%) | 4 (50.0%) | 12 (80.0%) | 53 80.3%) | 23 (76.7%) | 13 (81.3%) | 17 (85.0%) |  |
| 2 | 7 (7.0%) | 3 (8.8%) | 0 (0%) | 2 (25.0%) | 1 (6.7%) | 4 (6.1%) | 0 (0%) | 2 (12.5%) | 2 (10.0%) |  |
| 3 | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |  |
| Symptoms | 82 (82.0%) | 25 (73.5%) | 6 (54.5%) | 6 (75.0%) | 13 (86.7%) | 57 (86.4%) | 23 (76.7%) | 15 (93.8%) | 19 (95.0%) | **0.039** |
| Duration of symptoms\* (days) | 2.00 (2.00) | 2.5 (5.5) | 2.00 (0) | 2.00 (0) | 5.00 (4.00) | 2.00 (2.00) | 2.00 (2.00) | 2.00 (1.00) | 3.00 (2.00) | 0.060 |
| Cough | 36 (36.0%) | 10 (29.4%) | 0 (0%) | 1 (12.5%) | 9 (60.0%) | 26 (39.4%) | 8 (26.7%) | 8 (50.0%) | 10 (50.0%) | **0.007** |
| Duration of cough (days) | 4.00 (4.25) | 5.5 (4.75) | **-** | 10.0 (0) | 4.00 (5.00) | 4.00 (2.75) | 3.00 (2.50) | 3.50 (1.00) | 6.50 (3.00) | 0.105 |
| Fever | 62 (62.0%) | 21 (61.8%) | 5 (45.5%) | 4 (50.0%) | 12 (80.0%) | 41 (62.1%) | 14 (46.7%) | 14 (87.5%) | 13 (65.0%) | **0.046** |
| Maximum value (°C) | 38.25 (0.68) | 38.00 (0.25) | 38.2 (0.500) | 38.0 (0.150) | 38.0 (0.825) | 38.50 (0.70) | 38.2 (0.500) | 38.6 (0.875) | 38.5 (0.600) | 0.626 |
| Duration of fever (days) | 2.00 (1.00) | 2.00 (1.00) | 2.00 (0) | 2.00 (1.50) | 3.00 (3.00) | 2.00 (1.00) | 1.50 (1.00) | 2.00 (2.00) | 2.00 (1.00) | **0.020** |
| Sore throat (pharyngula) | 21 (21.0%) | 2 (5.9%) | 0 (0%) | 0 (0%) | 2 (13.3%) | 19 (28.8%) | 9 (30.0%) | 2 (12.5%) | 8 (40.0%) | **0.034** |
| Nasal congestion/discharge | 37 (37.0%) | 6 (17.6%) | 1 (9.1%) | 1 (12.5%) | 4 (26.7%) | 31 (47.0%) | 13 (43.3%) | 7 (43.8%) | 11 (55.0%) | 0.074 |
| Duration of nasal congestion (days) | 3.00 (3.00) | 2.00 (2.25) | 5.00 (0) | 2.00 (0) | 2.00 (1.25) | 4.00 (3.00) | 2.00 (3.00) | 4.00 (1.50) | 4.00 (3.00) | 0.247 |
| Headache | 24 (24.0%) | 5 (14.7%) | 1 (9.1%) | 0 (0%) | 4 (26.7%) | 19 (28.8%) | 8 (26.7%) | 6 (37.5%) | 5 (25.0%) | 0.342 |
| Headache intensity |  |  |  |  |  |  |  |  |  |  |
| Severe | 10 (10.0%) | 5 (14.7%) | 1 (9.1%) | 0 (0%) | 4 (26.7%) | 5 (76%) | 2 (6.7%) | 2 (12.5%) | 1 (5.0%) | 0.144 |
| Mild | 14 (14.0%) | 0 (0.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 14 (21.2%) | 6 (20.0%) | 4 (25.0%) | 4 (20.0%) |  |
| Fatigue | 30 (30.0%) | 7 (20.6%) | 3 (27.3%) | 0 (0%) | 4 (26.7%) | 23 (34.8%) | 13 (43.3%) | 5 (31.3%) | 5 (25.0%) | 0.275 |
| Taste disorders | 11 (11.0%) | 7 (20.6%) | 1 (9.1%) | 1 (12.5%) | 5 (33.3%) | 4 (6.1%) | 2 (6.7%) | 2 (12.5%) | 0 (0%) | 0.056 |
| Duration of taste disorders | 4.00 (4.00) | 7.00 (5.50) | 2.00 (0) | 4.00 (0) | 7.00 (3.00) | 3.50 (1.00) | 3.00 (0) | 4.00 (0) | - | 0.383 |
| Smell disorders | 9 (9.0%) | 7 (20.6%) | 2 (18.2%) | 0 (0%) | 5 (33.3%) | 2 (3.0%) | 1 (3.3%) | 1 (6.3%) | 0 (0%) | **0.007** |
| Duration of smell disorders (days) | 7.00 (8.00) | 7.00 (7.50) | 16.0 (14.0) | - | 7.00 (3.00) | 2.00 (1.00) | 1.00 (0) | 3.00 (0) | - | 0.525 |
| GI symptoms | 8 (8.0%) | 1 (2.9%) | 0 (0%) | 0 (0%) | 1 (6.7%) | 7 (10.6%) | 3 (10.0%) | 1 (6.3%) | 3 (15.0%) | 0.662 |
| Appetite disorders |  |  |  |  |  |  |  |  |  |  |
| No | 96 (96.0%) | 32 (94.1%) | 11 (100%) | 7 (87.5%) | 14 (93.3%) | 64 (97.0%) | 30 (100%) | 16 (100%) | 18 (90.0%) | 0.371 |
| Increased | 2 (2.0%) | 1 (2.9%) | 0 (0%) | 1 (12.5%) | 0 (0%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 1 (5.0%) |  |
| Decreased | 2 (2.0%) | 1 (2.9%) | 0 (0%) | 0 (0%) | 1 (6.7%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 1 (5.0%) |  |
| Dyspnoea | 1 | 0 (0.0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (1.5%) | 0 (0%) | 0 (0%) | 1 (5.0%) | 0.544 |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VOCs: variants of concern; WTS: wild type strain; N/A: not applicable; GI: gastrointestinal.

Table II. Overview of symptoms of SARS-CoV-2 positive adult (≥18 age years) participants among VOCs.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants ≥18 age years old | Total | Non-Omicron variants (total) | Non-Omicron variants | | | Omicron variants (total) | Omicron variants | | | P-value |
| WTS | Alpha | Delta | Omicron BA.1 | Omicron BA.2 | Omicron BA.4/BA.5 |
|  | (N=813) | (N=474) | (N=176) | (N=156) | (N=142) | (N=339) | (N=142) | (N=109) | (N=88) |  |
| Severity |  |  |  |  |  |  |  |  |  |  |
| 0 | 51 (6.3%) | 26 (5.5%) | 11 (6.3%) | 7 (4.5%) | 8 (5.6%) | 25 (7.4%) | 11 (7.7%) | 9 (8.3%) | 5 (5.7%) | **<0.001** |
| 1 | 577 (71.0%) | 302 (63.7%) | 129 (73.3%) | 90 (57.7%) | 83 (58.5%) | 275 (81.1%) | 117 (82.4%) | 88 (80.7%) | 70 (79.5%) |  |
| 2 | 148 (18.2%) | 115 (24.3%) | 30 (17.0%) | 47 (30.1%) | 38 (26.8%) | 33 (9.7%) | 11 (7.7%) | 11 (10.1%) | 11 (12.5%) |  |
| 3 | 37 (4.6%) | 31 (6.5%) | 6 (3.4%) | 12 (7.7%) | 13 (9.2%) | 6 (1.8%) | 3 (2.1%) | 1 (0.9%) | 2 (2.3%) |  |
| Symptoms | 762 (93.7%) | 448 (94.5%) | 165 (93.8%) | 149 (95.5%) | 134 (94.4%) | 314 (92.6%) | 131 (92.3%) | 100 (91.7%) | 83 (94.3%) | 0.813 |
| Duration of symptoms\* (days) | 5.00 (7.00) | 7.00 (7.00) | 6.00 (7.00) | 10.0 (10.0) | 7.00 (6.75) | 5.00 (3.00) | 5.00 (4.00) | 5.00 (3.00) | 4.00 (3.00) | **<0.001** |
| Cough | 328 (40.3%) | 184 (38.8%) | 70 (39.8%) | 58 (37.2%) | 56 (39.4%) | 144 (42.5%) | 58 (40.8%) | 47 (43.1%) | 39 (44.3%) | 0.894 |
| Duration of cough (days) | 7.00 (6.00) | 7.00 (5.00) | 7.00 (8.75) | 7.00 (5.75) | 7.00 (5.00) | 6.00 (6.00) | 7.00 (5.00) | 5.00 (4.50) | 6.00 (8.00) | 0.187 |
| Fever | 607 (74.7%) | 381 (80.4%) | 144 (81.8%) | 124 (79.5%) | 113 (79.6%) | 226 (66.7%) | 92 (64.8%) | 71 (65.1%) | 63 (71.6%) | **<0.001** |
| Maximum value (°C) | 38.0 (0.80) | 38.0 (0.50) | 38.0 (0.80) | 38.0 (0.70) | 38.3 (0.80) | 38.0 (1.05) | 38.0 (0.90) | 38.0 (1.00) | 38.5 (1.00) | **<0.001** |
| Duration of fever (days) | 3.00 (2.00) | 3.00 (4.00) | 3.00 (4.25) | 3.00 (4.00) | 3.00 (3.00) | 2.00 (1.00) | 2.00 (1.25) | 2.00 (2.00) | 2.00 (1.00) | **<0.001** |
| Sore throat (pharyngula | 237 (29.2%) | 98 (20.7%) | 42 (23.9%) | 29 (18.6%) | 27 (19.0%) | 139 (41.0%) | 64 (45.1%) | 40 (36.7%) | 35 (39.8%) | **<0.001** |
| Nasal congestion/discharge | 269 (33.1%) | 101 (21.3%) | 42 (23.9%) | 29 (18.6%) | 30 (21.1%) | 168 (49.6%) | 72 (50.7%) | 55 (50.5%) | 41 (46.6%) | **<0.001** |
| Duration of nasal congestion(days) | 5.00 (4.00) | 5.00 (5.00) | 5.00 (3.00) | 4.00 (7.00) | 5.00 (7.00) | 5.00 (3.00) | 5.00 (3.00) | 5.00 (4.00) | 5.00 (3.00) | 0.211 |
| Headache | 337 (41.5%) | 179 (37.8%) | 89 (50.6%) | 49 (31.4%) | 41 (28.9%) | 158 (46.6%) | 65 (45.8%) | 45 (41.3%) | 48 (54.5%) | **<0.001** |
| Headache intensity |  |  |  |  |  |  |  |  |  |  |
| Severe | 253 (31.1%) | 150 (31.6%) | 74 (42.0%) | 38 (24.4%) | 38 (26.8%) | 103 (30.4%) | 39 (27.5%) | 25 (22.9%) | 39 (44.3%) | **<0.001** |
| Mild | 84 (10.3%) | 29 (6.1%) | 15 (8.5%) | 11 (7.1%) | 3 (2.1%) | 55 (16.2%) | 26 (18.3%) | 20 (18.3%) | 9 (10.2%) |  |
| Fatigue | 466 (57.3%) | 255 (53.8%) | 98 (55.7%) | 83 (53.2%) | 74 (52.1%) | 211 (62.2%) | 75 (52.8%) | 68 (62.4%) | 68 (77.3%) | **0.002** |
| Taste disorders | 209 (25.7%) | 164 (34.6%) | 79 (44.9%) | 48 (30.8%) | 37 (26.1%) | 45 (13.3%) | 18 (12.7%) | 11 (10.1%) | 16 (18.2%) | **<0.001** |
| Duration of taste disorders | 7.00 (9.00) | 8.00 (7.00) | 7.00 (3.75) | 7.00 (7.00) | 12.5 (9.25) | 5.00 (7.00) | 5.00 (5.25) | 4.00 (3.00) | 5.00 (12.3) | **<0.001** |
| Smell disorders | 183 (22.5%) | 146 (30.8%) | 70 (39.8%) | 39 (25.0%) | 37 (26.1%) | 37 (10.9%) | 17 (12.0%) | 8 (7.3%) | 12 (13.6%) | **<0.001** |
| Duration of smell disorders (days) | 7.00 (8.00) | 7.00 (7.25) | 7.00 (4.00) | 7.00 (6.00) | 12.5 (9.25) | 5.00 (7.00) | 5.00 (3.00) | 4.50 (6.25) | 4.50 (8.75) | **<0.001** |
| GI symptoms | 152 (18.7%) | 96 (20.3%) | 35 (19.9%) | 49 (31.4%) | 12 (8.5%) | 56 (16.5%) | 20 (14.1%) | 11 (10.1%) | 25 (28.4%) | **<0.001** |
| Appetite disorders |  |  |  |  |  |  |  |  |  |  |
| No | 746 (91.8%) | 433 (91.4%) | 169 (96.0%) | 125 (80.1%) | 139 (97.9%) | 313 (92.3%) | 135 (95.1%) | 102 (93.6%) | 76 (86.4%) | **<0.001** |
| Increased | 11 (1.4%) | 7 (1.5%) | 1 (0.6%) | 6 (3.8%) | 0 (0%) | 4 (1.2%) | 3 (2.1%) | 1 (0.9%) | 0 (0%) |  |
| Decreased | 56 (6.9%) | 34 (7.2%) | 6 (3.4%) | 25 (16.0%) | 3 (2.1%) | 22 (6.5%) | 4 (2.8%) | 6 (5.5%) | 12 (13.6%) |  |
| Dyspnoea | 138 (17.0%) | 111 (23.4%) | 35 (19.9%) | 37 (23.7%) | 39 (27.5%) | 27 (8.0%) | 12 (8.5%) | 6 (5.5%) | 9 (10.2%) | **<0.001** |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VOCs: variants of concern; WTS: wild type strain; GI: gastrointestinal.

Table III. Overview of disease outcomes of SARS-CoV-2 positive adult (≥18 age years) participants among VOCs.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Participants >=18 age years old | Total | Non-Omicron variants (total) | Non-Omicron variants | | | Omicron variants (total) | Omicron variants | | | P-value |
| WTS | Alpha | Delta | BA.1 | BA.2 | BA.4/BA.5 |
|  | 813 | 474 | (N=176) | (N=156) | (N=142) | 339 | (N=142) | (N=109) | (N=88) |  |
| Hospitalization because of COVID-19 | 172 (21.2%) | 145 (30.6%) | 36 (20.5%) | 58 (37.2%) | 51 (35.9%) | 27 (8.0%) | 14 (9.9%) | 12 (11.0%) | 13 (14.8%) | **<0.001** |
| Duration of Hospitalization (days) | 6.00 (6.00) | 6.00 (6.00) | 7.00 (5.75) | 6.00 (7.50) | 6.00 (5.00) | 5.00 (5.00) | 6.50 (8.25) | 4.00 (2.25) | 3.00 (2.00) | 0.084 |
| Diagnosis of pneumonia | 123 (15.1%) | 109 (23.0%) | 29 (16.5%) | 39 (25.0%) | 41 (28.9%) | 14 (4.1%) | 9 (6.3%) | 3 (2.8%) | 2 (2.3%) | **<0.001** |
| HDU | 15 (1.5%) | 13 (2.7%) | 5 (2.8%) | 3 (1.9%) | 5 (3.5%) | 2 (0.6%) | 1 (0.7%) | 1 (0.9%) | 0 (0%) | 0.272 |
| Duration of HDU (days) | 9.00 (5.00) | 9.00 (3.00) | 6.00 (3.00) | 9.00 (4.00) | 9.00 (6.00) | 27.5 (12.50) | 40.0 (0) | 15.0 (0) | - | 0.255 |
| Hospitalization in ICU | 16 (2.0%) | 15 (3.2%) | 5 (2.8%) | 4 (2.6%) | 6 (4.2%) | 1 (0.3%) | 1 (0.7%) | 0 (0%) | 0 (0%) | 0.079 |
| Duration in ICU (days) | 11.50 (14.75) | 10.00 (14.00) | 10.0 (4.00) | 5.50 (8.00) | 21.0 (6.00) | 36.0 (0) | 36.0 (0) | - | - | 0.247 |
| Intubation | 17 (2.1%) | 15 (3.2%) | 5 (2.8%) | 4 (2.6%) | 6 (4.2%) | 2 (0.6%) | 1 (0.7%) | 1 (0.9%) | 0 (0%) | 0.170 |
| Duration of intubation (days) | 9.00 (7.00) | 9.00 (6.50) | 9.00 (4.00) | 7.50 (5.50) | 9.00 (8.75) | 11.50 (1.50) | 10.0 (0) | 13.0 (0) | - | 0.835 |
| Death | 35 (4.3%) | 29 (6.1%) | 5 (2.8%) | 11 (7.1%) | 13 (9.2%) | 6 (1.8%) | 3 (2.1%) | 1 (0.9%) | 2 (2.3%) | **0.004** |

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; VOCs: variants of concern; WTS: wild type strain; COVID-19: coronavirus disease 2019; HDU: high dependency care units; ICU: intensive care units; GI: gastrointestinal.

Table IV. Multivariate analysis of hospitalization, pneumonia, ICU admission, intubation and death in Omicron and non-Omicron variants among adult participants.

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Hospitalization | | | | | | Pneumonia | | | | | | ICU | | | Intubation | | | Death | | |
| Non-Omicron (N=474) | | | Omicron (N=339) | | | Non-Omicron (N=474) | | | Omicron (N=339) | | | Non-Omicron (N=474) | | | Non-Omicron (N=474) | | | Non-Omicron (N=474) | | |
|  | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value | OR | 95% C.I. | P-value |
| Age | 1.06 | 1.05 – 1.09 | **<0.001** | 1.14 | 1.09 – 1.21 | **<0.001** | 1.06 | 1.04 – 1.08 | **<0.001** | 1.08 | 1.03 – 1.15 | **0.006** | 1.04 | 1.00 – 1.09 | 0.054 | 1.05 | 1.00 – 1.10 | **0.038** | 1.07 | 1.04 – 1.12 | **<0.001** |
| Sex (M/F) | 1.68 | 1.01 – 2.81 | **0.047** | 1.89 | 0.62 – 5.99 | 0.265 | 1.67 | 0.98 – 2.88 | 0.059 | 4.66 | 0.82 – 41.19 | 0.109 | 3.34 | 0.95 – 14.09 | 0.074 | 3.56 | 0.97 – 15.64 | 0.067 | 3.24 | 1.17 – 9.73 | **0.028** |
| Autoimmune/ autoinflammatory diseases | 8.56 | 2.36 – 32.44 | **0.001** | 0.67 | 0.12 – 2.85 | 0.607 | 2.32 | 0.57 – 8.31 | 0.209 | 0.28 | 0.01 – 2.60 | 0.333 | 2.14 | 0.09 – 18.82 | 0.551 | - | - | 0.991 | 3.06 | 0.24 – 25.18 | 0.338 |
| Dementia/Insomnia/ Neurological disorders | 0.88 | 0.41 – 1.88 | 0.749 | 9.07 | 1.57 – 57.28 | **0.015** | 1.01 | 0.48 – 2.09 | 0.971 | 0.71 | 0.03 – 8.60 | 0.801 | 0.64 | 0.11 – 2.68 | 0.573 | 0.66 | 0.12 – 2.72 | 0.593 | 1.77 | 0.61 – 4.90 | 0.280 |
| Respiratory system disorders | 2.07 | 0.75 – 5.76 | 0.156 | 0.98 | 0.12 – 6.41 | 0.980 | 3.46 | 1.33 – 9.14 | **0.011** | 3.19 | 0.20 – 39.26 | 0.373 | 0.64 | 0.07 – 3.71 | 0.655 | 1.04 | 0.15 – 5.26 | 0.968 | 1.05 | 0.20 – 4.32 | 0.950 |
| Malignancies | 18.93 | 2.68 – 392.66 | **0.012** | 7.49 | 1.29 – 46.48 | **0.026** | 2.45 | 0.54 – 12.27 | 0.252 | 0.54 | 0.01 – 8.97 | 0.702 | 1.96 | 0.09 – 15.83 | 0.580 | 1.52 | 0.07 – 12.18 | 0.733 | 0.41 | 0.02 – 3.16 | 0.463 |
| Hematological disorders | 2.75 | 0.64 – 11.31 | 0.160 | 21.49 | 1.11 – 412.54 | **0.046** | 1.56 | 0.35 – 6.11 | 0.539 | 9.16 | 0.25 – 278.15 | 0.185 | 1.58 | 0.06 – 13.13 | 0.719 | 3.33 | 0.32 – 22.22 | 0.251 | 2.40 | 0.32 – 14.07 | 0.357 |
| GI system disorders | 0.66 | 0.13 – 2.92 | 0.588 | 0.69 | 0.00 – 101.13 | 0.897 | 1.31 | 0.30 – 5.28 | 0.709 | - | - | 0.999 | 2.59 | 0.12 – 20.85 | 0.430 | 2.63 | 0.12 – 21.54 | 0.424 | 6.95 | 1.11 – 39.09 | **0.029** |
| Immunosuppression/Pregnancy | 1.86 | 0.07 – 21.33 | 0.649 | - | - | 0.993 | - | - | 0.984 | - | - | 0.999 | - | - | 0.991 | - | - | 0.996 | - | - | 0.991 |
| Cardiovascular diseases | 0.86 | 0.47 – 1.57 | 0.628 | 0.59 | 0.13 – 2.45 | 0.473 | 0.84 | 0.44 – 1.58 | 0.588 | 5.54 | 0.76 – 59.10 | 0.115 | 0.81 | 0.16 – 4.21 | 0.794 | 1.01 | 0.19 – 6.21 | 0.992 | 1.64 | 0.44 – 6.98 | 0.476 |
| Metabolic disorders/ endocrinopathies | 1.98 | 1.10 – 3.58 | **0.023** | 1.87 | 0.49 – 7.10 | 0.354 | 1.69 | 0.93 – 3.05 | 0.084 | 0.39 | 0.01 – 4.38 | 0.489 | 6.13 | 1.76 – 23.95 | **0.006** | 5.57 | 1.57 – 22.41 | **0.010** | 2.07 | 0.78 – 5.50 | 0.141 |
| Urogenital disorders | 2.17 | 0.76 – 6.51 | 0.154 | 0.40 | 0.00 – 43.29 | 0.742 | 1.61 | 0.58 – 4.41 | 0.354 | - | - | 0.999 | 2.10 | 0.36 – 9.52 | 0.365 | 1.78 | 0.29 – 8.32 | 0.489 | 1.61 | 0.39 – 5.88 | 0.484 |
| Other\* | 5.07 | 1.99 – 13.76 | **0.001** | 12.51 | 1.09 – 125.70 | **0.036** | 2.07 | 0.89 – 4.87 | 0.091 | 5.81 | 0.21 – 168.62 | 0.304 | 1.73 | 0.31 – 7.27 | 0.481 | 1.94 | 0.38 – 8.01 | 0.384 | 1.75 | 0.55 – 5.14 | 0.322 |
| Vaccination | 0.12 | 0.05 – 0.28 | **<0.001** | 0.12 | 0.03 – 0.37 | **<0.001** | 0.27 | 0.12 – 0.57 | **0.001** | 0.04 | 0.00 – 0.22 | **0.001** | 0.16 | 0.01 – 0.97 | 0.098 | 0.15 | 0.01 – 0.91 | 0.085 | 0.22 | 0.05 – 0.78 | **0.028** |
| Previous SARS-CoV-2 infection | - | - | - | 0.37 | 0.02 – 3.13 | 0.425 | - | - | - | - | - | 0.995 | - | - | - | - | - | - | - | - | - |

ICU: intensive care units; OR: odds ratio; C.I.: confidence interval; GI: gastrointestinal; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2.

\*Other: Skin diseases, genetic disorders, intraocular hypertension, benign intracranial hypertension